2. Food and Drugs Administration. Highlights of Prescribing Information: Oseltamivir. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021087s057lbl.pdf
3. Therapeutic Goods Administration. Oseltamivir Phosphate. 2021. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2012-PI-02051-3&d=202004151016933
12. Karadag-Oncel E, Ceyhan M. Oseltamivir in neonates, infants and young children: a focus on clinical pharmacology. Infect Disord Drug Targets. 2013 Feb;13(1):15-24.
15. Chen R, Fang Z, Huang Y. Neuropsychiatric events in an adult patient with influenza a (H3N2) treated with oseltamivir (Tamiflu): a case report. BMC Infect Dis. 2019 Mar 4;19(1):224.
16. Antipov EA, Pokryshevskaya EB. The effects of adverse drug reactions on patients' satisfaction: Evidence from publicly available data on Tamiflu (oseltamivir). Int J Med Inform. 2019 May;125:30-36.
17. Fang S, Qi L, Zhou N, Li C. Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir: A case report. Medicine (Baltimore). 2018 Sep;97(38):e12497.
18. Drugs and Lactation Database. Bethesda (MD): National Institute of Child Health and Human Development; 2023. Oseltamivir. https://www.ncbi.nlm.nih.gov/books/NBK501493/
19. Sur M, Lopez MJ, Baker MB. Oseltamivir.In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. https://www.ncbi.nlm.nih.gov/books/NBK539909/